AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31126577 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion-Distraction (FD) technique
Number of subjects: 150
Study 31126577 — intervention group
Group type: COMPARATOR
Intervention: High-Velocity Low-Back Spinal Manipulation (HVLA-SM)
Number of subjects: 150
Study 29025631 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) for 6 months
Number of subjects: 2056
Study 29025631 — intervention group
Group type: COMPARATOR
Intervention: No isoniazid preventive therapy (no IPT)
Number of subjects: 2056
Study 25344466 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable monitoring at home (STDHome)
Number of subjects: 58
Study 25344466 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable monitoring in sleep laboratory (PSG_STDLab)
Number of subjects: 58
Study 25344466 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe cases diagnosed with portable monitoring
Number of subjects: 58
Study 25344466 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall diagnostic accuracy of portable monitoring
Number of subjects: 58
Study 24335920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 385
Study 24335920 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 385
Study 21969450 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise (END, n = 10)
Number of subjects: 23
Study 21969450 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RES, n = 13)
Number of subjects: 23
Study 21969450 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise (END)
Number of subjects: 23
Study 21969450 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RES)
Number of subjects: 23
Study 21969450 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining after END
Number of subjects: 23
Study 19156015 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical contact lenses
Number of subjects: 30
Study 19156015 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric contact lenses
Number of subjects: 30
Study 19156015 — intervention group
Group type: COMPARATOR
Intervention: Wearing no lens
Number of subjects: 30
Study 19156015 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency toric lens
Number of subjects: 30
Study 19156015 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue Advance for Astigmatism (thin-zone design)
Number of subjects: 30
Study 19156015 — intervention group
Group type: EXPERIMENTAL
Intervention: SofLens toric
Number of subjects: 30
Study 19156015 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric lenses (excluding Acuvue Advance for Astigmatism)
Number of subjects: 30
Study 17451643 — intervention group
Group type: EXPERIMENTAL
Intervention: ABA condition
Number of subjects: 0
Study 17451643 — intervention group
Group type: COMPARATOR
Intervention: AAA condition
Number of subjects: 0
Study 17451643 — intervention group
Group type: COMPARATOR
Intervention: ABC condition
Number of subjects: 0
Study 17451643 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy ratings
Number of subjects: 0
Study 17451643 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodermal responses
Number of subjects: 0
Study 15614241 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 visits per week for 3 weeks
Number of subjects: 24
Study 15614241 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 visits per week for 3 weeks
Number of subjects: 24
Study 15614241 — intervention group
Group type: COMPARATOR
Intervention: 1 visit per week for 3 weeks
Number of subjects: 24
Study 11309004 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte depleting arterial line filter (Pall LG6)
Number of subjects: 60
Study 11309004 — intervention group
Group type: COMPARATOR
Intervention: No arterial line filter
Number of subjects: 60
Study 9128209 — intervention group
Group type: EXPERIMENTAL
Intervention: oHBP using a validated fully automated oscillometric device (Omron HEM‐705CP)
Number of subjects: 46
Study 9128209 — intervention group
Group type: COMPARATOR
Intervention: sHBP using calibrated aneroid devices
Number of subjects: 46
Study 12369756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of glimepiride (1.0 mg)
Number of subjects: 12
Study 12369756 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride tablet (1.0 mg)
Number of subjects: 12
Study 3479527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiracetam 800 mg bid
Number of subjects: 40
Study 3479527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30453597 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated casein and sucrose mixture (active)
Number of subjects: 59
Study 30453597 — intervention group
Group type: COMPARATOR
Intervention: Control product (non-encapsulated)
Number of subjects: 59
Study 27843950 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CPP-ACP paste
Number of subjects: 21
Study 27843950 — intervention group
Group type: COMPARATOR
Intervention: 5% sodium fluoride varnish (FV)
Number of subjects: 21
Study 27843950 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CPP-ACP paste and 5% sodium fluoride varnish (CPP-ACP-FV)
Number of subjects: 21
Study 27843950 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 21
Study 25480348 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 48
Study 25480348 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day plus alfacalcidol 1 μg
Number of subjects: 48
Study 25480348 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 22546009 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone-artesunate (CDA)
Number of subjects: 351
Study 22546009 — intervention group
Group type: COMPARATOR
Intervention: Other artemisinin-based combination therapies (ACT)
Number of subjects: 351
Study 22546009 — intervention group
Group type: EXPERIMENTAL
Intervention: G6PD deficiency
Number of subjects: 351
Study 22546009 — intervention group
Group type: EXPERIMENTAL
Intervention: Both G6PD deficiency and CDA treatment
Number of subjects: 351
Study 20722560 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis (PD)
Number of subjects: 120
Study 20722560 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 120
Study 20722560 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 120
Study 20722560 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 120
Study 20722560 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of dialysis treatments
Number of subjects: 120
Study 18222001 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative ocular therapies and chemothermotherapy (intravenous carboplatin followed by transpupillary thermotherapy) after chemoreduction by 2 cycles of carboplatin and etoposide
Number of subjects: 83
Study 18222001 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (2 cycles of carboplatin and etoposide) followed by ocular therapy and chemothermotherapy
Number of subjects: 83
Study 18222001 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with ocular therapy and chemothermotherapy
Number of subjects: 83
Study 16152837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pifubing Xuedu Pill (PXDP) combined with Diyin Tablet (DYT)
Number of subjects: 60
Study 16152837 — intervention group
Group type: COMPARATOR
Intervention: Diyin Tablet (DYT) alone
Number of subjects: 60
Study 16152837 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of total effective rate
Number of subjects: 60
Study 16152837 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of clinical cured rate
Number of subjects: 60
Study 16152837 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxic and adverse reactions
Number of subjects: 60
Study 12063530 — intervention group
Group type: EXPERIMENTAL
Intervention: Injected heparin
Number of subjects: 22
Study 12063530 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled heparin
Number of subjects: 22
Study 12063530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9987495 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant radiochemotherapy (GITSG trial)
Number of subjects: 0
Study 9987495 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (Bakkevold trial)
Number of subjects: 0
Study 9987495 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiochemotherapy (EORTC-GITCCG trial)
Number of subjects: 0
Study 9987495 — intervention group
Group type: COMPARATOR
Intervention: Regional chemotherapy (historical control trials)
Number of subjects: 0
Study 9987495 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative or postoperative radiotherapy
Number of subjects: 0
Study 9987495 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative neoadjuvant radiochemotherapy
Number of subjects: 0
Study 9987495 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic and regional chemotherapy
Number of subjects: 0
Study 7838635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric feeding
Number of subjects: 48
Study 7838635 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpyloric feeding
Number of subjects: 48
Study 7838635 — intervention group
Group type: EXPERIMENTAL
Intervention: Small volume feeding (4 mL/kg)
Number of subjects: 48
Study 7838635 — intervention group
Group type: EXPERIMENTAL
Intervention: Large volume feeding (10 mL/kg)
Number of subjects: 48
Study 7838635 — intervention group
Group type: EXPERIMENTAL
Intervention: One-third concentration formula
Number of subjects: 48
Study 7838635 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-thirds concentration formula
Number of subjects: 48
Study 7838635 — intervention group
Group type: EXPERIMENTAL
Intervention: Full concentration formula
Number of subjects: 48
Study 1978770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg/d
Number of subjects: 30
Study 1978770 — intervention group
Group type: COMPARATOR
Intervention: Astemizole 10 mg/d
Number of subjects: 30
Study 639831 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone (5 to 20 mg single oral doses)
Number of subjects: 0
Study 639831 — intervention group
Group type: COMPARATOR
Intervention: Norethindrone from 2 different manufacturers
Number of subjects: 0
Study 31363457 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures (TCS)
Number of subjects: 150
Study 31363457 — intervention group
Group type: COMPARATOR
Intervention: Non-coated sutures (NCS)
Number of subjects: 150
Study 27862880 — intervention group
Group type: EXPERIMENTAL
Intervention: Supera® stenting after subintimal crossing
Number of subjects: 34
Study 25854295 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional social support in the intervention group
Number of subjects: 0
Study 25854295 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental social support in the intervention group
Number of subjects: 0
Study 25854295 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 23281706 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 0.3 mg·kg(‐1)
Number of subjects: 87
Study 23281706 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 4 μg·kg(‐1)
Number of subjects: 87
Study 22332395 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon 2 in the form of suppositories (genferon and viferon)
Number of subjects: 150
Study 18804331 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face counseling 40 days postpartum plus telephone counseling calls at 4 and 12 weeks later
Number of subjects: 0
Study 18804331 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus self-help material for each parent
Number of subjects: 0
Study 17098085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 522
Study 17098085 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 522
Study 17098085 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention follow-up (Intensive lifestyle intervention)
Number of subjects: 522
Study 17098085 — intervention group
Group type: COMPARATOR
Intervention: Post-intervention follow-up (Control group)
Number of subjects: 522
Study 15236629 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg pseudoephedrine
Number of subjects: 48
Study 15236629 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 48
Study 11231831 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse prevention program (2 primary care visits with a depression specialist and 3 telephone visits over 1 year)
Number of subjects: 386
Study 11231831 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse prevention program
Number of subjects: 386
Study 11231831 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 386
Study 9272773 — intervention group
Group type: COMPARATOR
Intervention: CEx (Control Exercise)
Number of subjects: 7
Study 9272773 — intervention group
Group type: COMPARATOR
Intervention: HEx (Heat Exercise)
Number of subjects: 7
Study 8385564 — intervention group
Group type: EXPERIMENTAL
Intervention: Amonafide (1600 mg/m2, 24-hour continuous infusion every 21 days)
Number of subjects: 72
Study 8385564 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetrexate (150 mg/m2, intravenous over 30 minutes every 2 weeks)
Number of subjects: 72
Study 3083793 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin infusion, 50 ng per kilogram of body weight per minute during cardiopulmonary bypass (CPB)
Number of subjects: 43
Study 3083793 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 patients)
Number of subjects: 43
Study 3083793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Prostacyclin and Control)
Number of subjects: 43
Study 31937267 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex gender-transformative intervention (engaging men for gender equality alongside women's participation in VSLAs)
Number of subjects: 0
Study 31937267 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for socioeconomic characteristics)
Number of subjects: 0
Study 29626232 — intervention group
Group type: COMPARATOR
Intervention: 0 g WP (placebo)
Number of subjects: 20
Study 29626232 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g WP
Number of subjects: 20
Study 29626232 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g WP
Number of subjects: 20
Study 29871205 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cellulose powder
Number of subjects: 50
Study 29871205 — intervention group
Group type: COMPARATOR
Intervention: Physiological sea water
Number of subjects: 50
Study 25173357 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (2 mg/kg trimethoprim + sulfamethoxazole daily for 12 months)
Number of subjects: 93
Study 25173357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 12 months)
Number of subjects: 93
Study 25173357 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 93
Study 25173357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 25173357 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal scan at 12 months (Antibiotic group)
Number of subjects: 93
Study 25173357 — intervention group
Group type: COMPARATOR
Intervention: Renal scan at 12 months (Placebo group)
Number of subjects: 93
Study 23516089 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk exercises based on the Bobath concept
Number of subjects: 0
Study 23516089 — intervention group
Group type: COMPARATOR
Intervention: Routine neurorehabilitation exercises
Number of subjects: 0
Study 23516089 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 0
Study 21565423 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive individualized bundling infection control measures
Number of subjects: 1874
Study 21565423 — intervention group
Group type: COMPARATOR
Intervention: Regular health care and regular measures for preventing HAIs
Number of subjects: 1874
Study 19236691 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 week programme of supervised aerobic exercises (twice weekly) and individually tailored brief intervention lifestyle counselling
Number of subjects: 144
Study 19236691 — intervention group
Group type: COMPARATOR
Intervention: Two hour education class on risk reduction post stroke
Number of subjects: 144
Study 19236691 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 1 year
Number of subjects: 144
Study 19236691 — intervention group
Group type: EXPERIMENTAL
Intervention: Health related quality of life measures
Number of subjects: 144
Study 19236691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular fitness measures
Number of subjects: 144
Study 16585412 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) for 2 weeks
Number of subjects: 46
Study 16585412 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental nocturnal oxygen for 2 weeks
Number of subjects: 46
Study 16585412 — intervention group
Group type: COMPARATOR
Intervention: Sham-CPAP for 2 weeks
Number of subjects: 46
Study 15147122 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (300 microg) + recombinant hepatitis B vaccine (40 microg)
Number of subjects: 54
Study 15147122 — intervention group
Group type: COMPARATOR
Intervention: Control group: recombinant hepatitis B vaccine (40 microg)
Number of subjects: 54
Study 10917242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary corticocancellous bone plug (group A)
Number of subjects: 60
Study 10917242 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 60
Study 8810206 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal eye drop preparation
Number of subjects: 157
Study 8810206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 1316076 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 400 mg lomefloxacin (Group I)
Number of subjects: 36
Study 1316076 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg lomefloxacin twice daily (Group II)
Number of subjects: 36
Study 3907504 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term diazepam prophylaxis (n = 152)
Number of subjects: 289
Study 3907504 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (n = 137)
Number of subjects: 289
Study 2874047 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of salbutamol 0.1 mg/kg followed by inhalation of 0.25 mg of ipratropium bromide
Number of subjects: 13
Study 2874047 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of ipratropium bromide and salbutamol
Number of subjects: 13
Study 2874047 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment with ipratropium bromide (two inhalations four times daily, 20 micrograms per inhalation) in combination with oral terbutaline and aerosolized salbutamol
Number of subjects: 13
Study 2874047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide treatment
Number of subjects: 13
Study 29606025 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual dietary plan for home with pre-discharge advice and three follow-up visits (one, four, and eight weeks)
Number of subjects: 144
Study 29606025 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 144
Study 28911067 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus bevacizumab (CAP-B) maintenance treatment
Number of subjects: 558
Study 28911067 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 558
Study 26021487 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibre intake (measured in quartiles)
Number of subjects: 15258
Study 26021487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal fibre intake
Number of subjects: 15258
Study 26021487 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable fibre intake
Number of subjects: 15258
Study 26021487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit fibre intake
Number of subjects: 15258
Study 26021487 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fibre intake (meta-analysis)
Number of subjects: 15258
Study 26021487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal fibre intake (meta-analysis)
Number of subjects: 15258
Study 26021487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit fibre intake (meta-analysis)
Number of subjects: 15258
Study 26021487 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable fibre intake (meta-analysis)
Number of subjects: 15258
Study 23404297 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (HP)
Number of subjects: 24
Study 23404297 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (HC)
Number of subjects: 24
Study 21554389 — intervention group
Group type: EXPERIMENTAL
Intervention: Steri‐Strip S
Number of subjects: 36
Study 21554389 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular suture
Number of subjects: 36
Study 18489014 — intervention group
Group type: COMPARATOR
Intervention: Transdermal nicotine (TN) 0 mg
Number of subjects: 124
Study 18489014 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TN) 7 mg
Number of subjects: 124
Study 18489014 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TN) 14 mg
Number of subjects: 124
Study 18489014 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TN) 21 mg
Number of subjects: 124
Study 18489014 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TN)
Number of subjects: 124
Study 16582054 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference randomised controlled trial (RCT) design
Number of subjects: 0
Study 12687882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrarapid train stimulation (UTS)
Number of subjects: 104
Study 12687882 — intervention group
Group type: COMPARATOR
Intervention: Conventional programmed electrical stimulation (PES)
Number of subjects: 104
Study 10741368 — intervention group
Group type: EXPERIMENTAL
Intervention: DIP joint fusion simulation on dominant hand
Number of subjects: 19
Study 10741368 — intervention group
Group type: COMPARATOR
Intervention: Nondominant hand (control)
Number of subjects: 19